Yahoo
NasdaqGM - Delayed Quote USD

Inventiva S.A. (IVA)

3.6500 -0.0800 (-2.14%)
At close: 4:00:01 PM EDT
Trade IVA on Coinbase
Chart Range Bar
Loading chart for IVA
  • Previous Close 3.7300
  • Open 3.6900
  • Bid 4.5500 x 100
  • Ask 4.4500 x 400
  • Day's Range 3.5850 - 3.7600
  • 52 Week Range 2.8200 - 7.2900
  • Volume 1,729,552
  • Avg. Volume 1,914,103
  • Market Cap (intraday) 862.205M
  • Beta (5Y Monthly) 1.00
  • PE Ratio (TTM) --
  • EPS (TTM) -0.6200
  • Earnings Date Sep 28, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 15.20
  • Zacks Rating Neutral

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.

inventivapharma.com

87

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .

YTD Return

IVA
21.00%
CAC 40 (^FCHI)
2.21%

1-Year Return

IVA
12.26%
CAC 40 (^FCHI)
2.30%

3-Year Return

IVA
1.35%
CAC 40 (^FCHI)
16.77%

5-Year Return

IVA
76.68%
CAC 40 (^FCHI)
16.68%

Earnings Trends

View More

Earnings Per Share (Normalized)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 1.31M
Earnings --
Profit Margin 0.00%

Q1

FY24

Q3

FY25

Q1

FY26

Q2

FY26

0
500K
1M
0.0%

Analyst Insights

View More

Analyst Price Targets

10.00
15.20 Average
3.6500 Current
26.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/2/2026
Analyst Truist Securities
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 13 -> 18

Statistics

View More

Valuation Measures

Annual
As of 10/28/2026
  • Market Cap

    867.37M

  • Enterprise Value

    676.41M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (current)

    --

  • Price/Sales (ttm)

    124.49

  • Price/Book (mrq)

    13.06

  • Enterprise Value/Revenue

    11.83k

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -42.69%

  • Return on Equity (ttm)

    -989.05%

  • Revenue (ttm)

    2.46M

  • Net Income Avi to Common (ttm)

    -247.72M

  • Diluted EPS (ttm)

    -0.6200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    166.13M

  • Total Debt/Equity (mrq)

    235.23%

  • Levered Free Cash Flow (ttm)

    -116.12M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

3.6500 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: